Nancy Stagliano

True North raises $45M in Series D toward rare drug trials

Rare disease focused and early-stage biotech True North Therapeutics (aka TNT) has raised $45 million in its latest funding round as it gears up for midstage tests for its lead candidate TNT009.

Ben Adams Oct 18, 2016 7:00am